Abstract: Provided is a retractor that makes it possible to reduce operation costs, is less likely to cause damage to surgical incision sites, do not reduce workability, and also makes it possible to easily maintain the desired surgical field and to change the surgical field or widen or narrow the area of the surgical field, depending on the surgical situation. The retractor 1 for holding a surgical incision open and maintaining a surgical field during an operation includes a belt-shaped body A made of a wire; and a connecting part B that is provided at one end portion of the belt-shaped body A and capable of being connected to another end portion or an intermediate portion of the belt-shaped body A so that the belt-shaped body A can be formed into a loop of a desired size.

Abstract: Provided is a retractor that makes it possible to reduce operation costs, is less likely to cause damage to surgical incision sites, do not reduce workability, and also makes it possible to easily maintain the desired surgical field and to change the surgical field or widen or narrow the area of the surgical field, depending on the surgical situation. The retractor 1 for holding a surgical incision open and maintaining a surgical field during an operation includes a belt-shaped body A made of a wire; and a connecting part B that is provided at one end portion of the belt-shaped body A and capable of being connected to another end portion or an intermediate portion of the belt-shaped body A so that the belt-shaped body A can be formed into a loop of a desired size.

Abstract: An administration method comprising: determining a cancer type through (i) first data indicating that an Estrogen Receptor (ER) is negative and a Human Epidermal growth factor Receptor-2 (Her2) is negative, or (ii) second data indicating that at least one of the ER and the Her2 is positive; and when the cancer type is determined through (i) the first data indicating that the ER is negative and the Her2 is negative: first performing a docetaxel administration cycle comprising administrating docetaxel to a patient multiple times at certain intervals; and then performing a 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) administration cycle comprising administrating 5-fluorouracil, epirubicin, and cyclophosphamide to the patient multiple times at certain intervals, and when the cancer type is determined through (ii) the second data indicating that at least one of the ER and Her2 is positive: first performing the FEC administration cycle; and then performing the docetaxel administration cycle.

Abstract: There was no device that proposes a method for administrating anti-cancer drugs according to each of cancer types. An administration method proposing device (100) includes an input unit (101) that receives an input of the cancer type of a cancer patient, an administration procedure determination unit (102) that determines the administration order of an FEC (F: 5-fluorouracil, E: epirubicin, and C: cyclophosphamide) administration cycle and a docetaxel administration cycle, and a display unit (103) that displays the administration order of the FEC administration cycle and the docetaxel administration cycle, as a result of the determination by the administration procedure determination unit (102).